Clinical trials: Heart Failure and Mildly Reduced Ejection Fraction
Iron Deficiency, Heart Failure With Reduced Ejection Fraction
Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
A significant percentage of patients with heart failure and reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) have iron deficiency who are symptomatic.
- Conditions
- Iron Deficiency, Heart Failure With Reduced Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
- Trial name
- NCT05992116
- Where
- Jordan
- Volunteers
- 450 people
- Sponsor
- Jordan Collaborating Cardiology Group
Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
An AI-ECG-Based Approach for Dynamic Assessment of Heart Failure Risk and Myocardial Recovery Following Atrial Fibrillation Ablation
Background Artificial intelligence-enabled electrocardiography (AI-ECG) has emerged as a promising digital biomarker for detecting latent myocardial dysfunction and predicting cardiovascular risk.
- Trial name
- NCT07708818
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Ewha Womans University Mokdong Hospital
Heart Failure, Heart Failure and Reduced Ejection Fraction
Selenium Intervention Registry Randomized Trial in Heart Failure
Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.
- Conditions
- Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction, Heart Failure and Preserved Ejection Fraction
- Trial name
- SIRI-HF (NCT07543562)
- Testing
- Selenium Supplement
- Where
- 11 sites in Norway, Sweden
- Volunteers
- 4,326 people
- Sponsor
- Skane University Hospital
Heart Failure, Heart Failure Preserved Ejection Fraction
Exercise, Mediterranean Diet and Inflammation in Heart Failure
This randomized clinical trial will test whether a multimodal anti-inflammatory program added to standard treatment improves the prognosis of patients with heart failure who have recently been hospitalized or visited the…
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Heart Failure, Diastolic (HFpEF), Chronic Inflammation
- Trial name
- FLARE-HF (NCT07885514)
- Testing
- Structured exercise training program, Mediterranean diet counseling, Standard heart failure management
- Volunteers
- 214 people
- Sponsor
- Hospital Severo Ochoa
Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction
CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction)
The clinical equipoise in the treatment of Atrial Fibrillation (AF) in patients with Heart Failure with mildly reduced Ejection Fraction/Heart Failure with Preserved Ejection Fraction (HFmrEF/HFpEF) reflects the scarcity of…
- Trial name
- NCT07254455
- Testing
- Catheter ablation
- Volunteers
- 900 people
- Sponsor
- Tulane University
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection…
- Trial name
- Elevate-HF (NCT07761117)
- Testing
- Elecoglipron
- Where
- 679 sites in United States, Argentina and 30 more
- Volunteers
- 6,950 people
- Sponsor
- AstraZeneca
Heart Failure and Preserved Ejection Fraction, Heart Failure
Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure
The goal of this clinical trial is to evaluate the impact of Finerenone on myocardial remodeling in patients with diabetic kidney disease (DKD) and heart failure with a left ventricular ejection fraction (LVEF) ≥ 40%.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- FINE-REMODEL (NCT07442448)
- Testing
- Finerenone
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Cathay General Hospital
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims.
- Trial name
- NCT06671314
- Where
- United States
- Volunteers
- 42,494 people
- Sponsor
- Novartis
Heart Failure and Reduced Ejection Fraction
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection…
- Trial name
- EVALUATE-HF (NCT02874794)
- Testing
- LCZ696 (sacubitril/valsartan), Enalapril
- Where
- 81 sites in United States
- Volunteers
- 465 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess…
- Trial name
- REMOD-REVERT (NCT05953831)
- Testing
- CDR132L
- Sponsor
- Cardior Pharmaceuticals GmbH
Heart Failure, Heart Failure and Reduced Ejection Fraction
Comparative Effects of Different Inspiratory Muscle Training Modalities in Patients With Heart Failure.
The purpose of this study is to compare the effects of three different modalities of inspiratory muscle training (IMT) in patients diagnosed with chronic heart failure who exhibit reduced or mid-range left ventricular ejection…
- Conditions
- Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction, Muscle Weakness
- Trial name
- IMT-HF-COMPARE (NCT07688863)
- Testing
- Mechanical Pressure-Threshold IMT Device, PowerBreathe KH2 Electronic IMT Device
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- Universidad Nacional Andres Bello
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction (HFrEF and HFmrEF)
Polypharmacy, Safety, and Medication Adherence in Patients With Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction
This prospective registry study (FARAON) aims to assess the prevalence, structure, safety profile, and dynamics of polypharmacy, as well as its association with medication adherence, quality of life, and clinical outcomes in…
- Trial name
- FARAON (NCT07640854)
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Iron Deficiency (ID), Heart Failure
Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure
The INITIATE-HF study is a cluster randomized controlled trial that aims to find out if reminding doctors about treatment guidelines for iron deficiency in adults with heart failure who are hospitalized and have evidence of iron…
- Conditions
- Iron Deficiency (ID), Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- INITIATE-HF (NCT07467668)
- Testing
- Notification Group, No Notification Group
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Kaiser Permanente
Heart Failure
Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
FINE-FOCUS study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Finerenone versus placebo on myocardial fibrosis and cardiac structure/function as assessed by…
- Trial name
- FINE-FOCUS (NCT07583173)
- Testing
- Oral finerenone
- Where
- China
- Volunteers
- 104 people
- Sponsor
- China National Center for Cardiovascular Diseases
Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction
CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection…
- Conditions
- Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
- Trial name
- CABA-HFPEF (NCT05508256)
- Testing
- CE-marked Catheter Ablation
- Where
- Germany
- Volunteers
- 1,548 people
- Sponsor
- Charite University, Berlin, Germany
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Heart Failure, Heart Failure and Reduced Ejection Fraction
Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fraction With Limited Kidney Function Assessments
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) constitutes of four medications that substantially reduce morbidity and mortality, and improve quality of life.
- Conditions
- Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- RESUME-HF (NCT07275437)
- Testing
- Blinded kidney function assessments
- Where
- 2 sites in Netherlands
- Volunteers
- 344 people
- Sponsor
- University Medical Center Groningen
Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild
[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction
Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Trial name
- NEURO-HF (NCT07856043)
- Testing
- [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stony Brook University
Heart Diseases, Cardiovascular Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Conditions
- Heart Diseases, Cardiovascular Diseases, Heart Failure
- Trial name
- EvolutionHF-DE (NCT06336330)
- Where
- 47 sites in Germany
- Volunteers
- 831 people
- Sponsor
- AstraZeneca